The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

RTW Investments bought 16,010,524 shares of Erasca last quarter; the estimated transaction value was $189.23 million based on the quarter's average share price. The position's quarter-end value rose ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning. By ...

Product development bottlenecks slow production timelines by forcing teams to wait on approvals, materials, design changes, testing, or unclear handoffs. Better planning, stronger visibility, and ...

In an effort to tackle the housing crisis, the Mamdani administration released a set of recommendations that would overhaul every part of the development process and could cut years off of schedules.

For small startups and academic spinoffs bringing their first molecules to market, reaching the clinic represents a major milestone. Reducing the time to investigate a new drug (IND) filing can help ...

Social media app X rolled out a new custom timeline feature earlier this week, and so far, user reactions have been positive. The new feature is reminiscent of TweetDeck, the popular feature that ...

This article originally appeared on PolitiFact. U.S. and Iran representatives are expected to meet this week in Pakistan to discuss an end to the war. Since the U.S. and Israel launched the strikes ...

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...